Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RESPONSE RATE AND PROGNOSTIC FACTORS OF RECURRENT OLIGODENDROGLIOMA TREATED WITH PROCARBAZINE, CCNU, AND VINCRISTINE CHEMOTHERAPY
Autore:
VANDENBENT MJ; KROS JM; HEIMANS JJ; PRONK LC; VANGROENINGEN CJ; KROUWER HGJ; TAPHOORN MJB; ZONNENBERG BA; TIJSSEN CC; TWIJNSTRA A; PUNT CJA; BOOGERD W;
Indirizzi:
DR DANIEL DEN HOED CANC CTR,DEPT NEUROONCOL,POB 5201 NL-3008 AE ROTTERDAM NETHERLANDS DR DANIEL DEN HOED CANC CTR,DEPT MED ONCOL NL-3008 AE ROTTERDAM NETHERLANDS UNIV HOSP DIJKZIGT,DEPT PATHOL NL-3015 GD ROTTERDAM NETHERLANDS VRIJE UNIV AMSTERDAM,UNIV HOSP,DEPT NEUROL & MED ONCOL AMSTERDAM NETHERLANDS UNIV UTRECHT HOSP,DEPT NEUROL & INTERNAL MED UTRECHT NETHERLANDS ST ELISABETHGASTHUIS,DEPT NEUROL TILBURG NETHERLANDS UNIV HOSP MAASTRICHT,DEPT NEUROL MAASTRICHT NETHERLANDS UNIV NIJMEGEN HOSP,DEPT MED ONCOL NIJMEGEN NETHERLANDS ANTONI VAN LEEUWENHOEK HUIS,NETHERLANDS CANC INST,DEPT NEUROONCOL AMSTERDAM NETHERLANDS
Titolo Testata:
Neurology
fascicolo: 4, volume: 51, anno: 1998,
pagine: 1140 - 1145
SICI:
0028-3878(1998)51:4<1140:RRAPFO>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; SALVAGE CHEMOTHERAPY; RADIATION-THERAPY; TUMORS; GLIOMAS; BRAIN; CELL; 19Q; 1P;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
M.J. Vandenbent et al., "RESPONSE RATE AND PROGNOSTIC FACTORS OF RECURRENT OLIGODENDROGLIOMA TREATED WITH PROCARBAZINE, CCNU, AND VINCRISTINE CHEMOTHERAPY", Neurology, 51(4), 1998, pp. 1140-1145

Abstract

Objectives: To determine the response rate and factors correlated with response of oligodendroglial tumors to procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy. Design: Retrospective, observational multicenter study. Methods: Patients treated with PCV or intensified PCV chemotherapy for a recurrent oligodendroglial tumor after surgery and radiation therapy with measurable disease were retrospectively evaluated for response. A 50% reduction in cross-sectional enhancingtumor area was considered a partial response. Stabilized or responding patients received six cycles of PCV unless unacceptable toxicity occurred. Results: Fifty-two patients were included; median time to progression (MTP) for the entire group was 10 months. In 17% of patients a complete response (MTP, 25 months) was obtained, and in 46% a partial response (MTP, 12 months) was obtained. Median overall survival was 20months. Although treatment was discontinued for toxicity in seven patients, it was generally well tolerated. The intensified PCV regimen was more toxic. Patients initially presenting with seizures and patientswith tumor necrosis in histologic specimens had a better response rate in contrast to patients who had their first relapse within 1 year offirst treatment (surgery and radiation therapy). Conclusions: Oligodendroglial tumors are chemosensitive, but most patients will have relapsed after 12 to 16 months. New studies must aim at improving initial treatment and second-line chemotherapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 13:15:06